Pharvaris CMO Sells Shares, Reduces Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Source: NASDAQ.COM
- Insider Selling: On May 1, 2026, Pharvaris N.V.'s Chief Medical Officer Peng Lu sold 14,166 common shares for approximately $427,000, representing 17.65% of his direct holdings, reducing ownership to 66,083 shares, indicating a cautious outlook on the company's future.
- Transaction Context: The sale was executed as part of a scheduled option exercise and immediate sale, with all shares coming from direct holdings and no indirect entities involved, demonstrating adherence to a 10b5-1 trading plan to mitigate insider trading risks.
- Financial Condition: Pharvaris reported cash and cash equivalents of €292 million for Q4 2025, a slight increase from €281 million the previous year, but still faced a €176 million annual loss with €124 million in R&D expenses, highlighting the high cost pressures typical of clinical-stage biotechs.
- Market Outlook: Despite recent clinical successes in the HAE treatment space and plans to submit an approval application in the first half of 2026, the company remains unprofitable and faces intense competition, necessitating careful evaluation of its future growth potential by investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHVS
Wall Street analysts forecast PHVS stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 29.860
Low
30.00
Averages
41.00
High
60.00
Current: 29.860
Low
30.00
Averages
41.00
High
60.00
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharvaris to Present Research Findings at EAACI Congress
- Research Presentation: Pharvaris will showcase eight research findings at the 2026 EAACI Congress, including one oral presentation and seven poster presentations, highlighting advancements in treating hereditary angioedema, which is expected to enhance the company's visibility in the biopharmaceutical sector.
- Oral Presentation Highlights: The oral presentation will be led by Dr. Mauro Cancian, focusing on the immediate treatment effects of oral Deucrictibant capsules for hereditary angioedema attacks, providing crucial data support for clinical applications and potentially increasing market acceptance of the product.
- Poster Presentation Content: Several poster presentations will cover safety assessments of Deucrictibant and its applications in various treatment regimens, likely attracting the attention of clinicians and fostering future collaborations and research opportunities.
- Market Authorization Preparation: Pharvaris is preparing marketing authorization applications for the Deucrictibant immediate-release capsule and conducting a global pivotal Phase 3 study, with significant data expected in Q3 2026, which will lay the groundwork for the company's future growth.
See More
Pharvaris Reports Q1 2026 Financial Results
- Financial Performance: Pharvaris reported a GAAP EPS of -€0.59 for Q1 2026, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company's cash and cash equivalents stood at €247 million, down from €292 million on December 31, 2025, reflecting liquidity pressures that may affect future operations.
- Funding Activity: Pharvaris is planning a $115 million stock offering aimed at strengthening its capital base, although this may dilute existing shareholders and potentially exert downward pressure on the stock price in the short term.
- Conference Presentations: Pharvaris showcased its research at several key conferences, including the CIIC Spring Conference and the AAAAI Annual Meeting, aiming to enhance its visibility and influence in the industry while fostering potential collaboration opportunities.
See More
Analysis of Insider Stock Transaction at Pharvaris N.V.
- Insider Stock Sale: On May 1, 2026, Pharvaris N.V.'s Chief Medical Officer, Peng Lu, sold 14,166 common shares for approximately $427,000 through a scheduled option exercise and immediate sale, indicating routine portfolio management rather than opportunistic trading.
- Equity Exposure Analysis: Post-transaction, Lu retains 66,083 direct shares valued at about $1.95 million, reflecting a 17.65% reduction in direct holdings, yet maintains substantial equity exposure through 205,000 stock options, aligning with shareholder interests.
- Financial Overview: Pharvaris N.V. has a market capitalization of $1.97 billion, and despite a net loss of $175.7 million in 2025, the company invested €124 million in R&D, showcasing its long-term strategic focus in the rare disease treatment sector.
- Clinical Progress and Market Outlook: The company is advancing therapies like PHA121 and PHVS416 for hereditary angioedema, with plans to submit a new drug application in the first half of 2026, which could solidify its competitive position in the market.
See More
Pharvaris CMO Sells Shares, Reduces Holdings
- Insider Selling: On May 1, 2026, Pharvaris N.V.'s Chief Medical Officer Peng Lu sold 14,166 common shares for approximately $427,000, representing 17.65% of his direct holdings, reducing ownership to 66,083 shares, indicating a cautious outlook on the company's future.
- Transaction Context: The sale was executed as part of a scheduled option exercise and immediate sale, with all shares coming from direct holdings and no indirect entities involved, demonstrating adherence to a 10b5-1 trading plan to mitigate insider trading risks.
- Financial Condition: Pharvaris reported cash and cash equivalents of €292 million for Q4 2025, a slight increase from €281 million the previous year, but still faced a €176 million annual loss with €124 million in R&D expenses, highlighting the high cost pressures typical of clinical-stage biotechs.
- Market Outlook: Despite recent clinical successes in the HAE treatment space and plans to submit an approval application in the first half of 2026, the company remains unprofitable and faces intense competition, necessitating careful evaluation of its future growth potential by investors.
See More
Pharvaris Prices Underwritten Offering of 3.87 Million Shares
- Offering Size: Pharvaris has priced an underwritten offering of 3.87 million ordinary shares at $29.68 per share, with gross proceeds expected to be approximately $115 million, which will provide crucial funding for the company's research and operations.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 581,199 ordinary shares, which may further enhance the company's capital structure and market liquidity.
- Market Reaction: Following the announcement of the offering, Pharvaris's stock traded 1.5% higher during pre-market hours on Friday, indicating a positive market response to the company's financing activities and potentially boosting investor confidence.
- Future Outlook: The offering is expected to close on or about May 11, 2026, with the funds aimed at supporting the company's further development and innovation in the global angioedema space, thereby enhancing its competitive position in the market.
See More
Pharvaris Prices Underwritten Offering of 3,874,664 Shares
- Offering Size: Pharvaris announced the pricing of 3,874,664 ordinary shares at $29.68 each, expecting to raise approximately $115 million, reflecting the company's strong financing capability and market confidence in the biopharmaceutical sector.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the offering, indicating robust support and professional partnerships in the capital markets.
- Additional Share Option: Pharvaris granted underwriters a 30-day option to purchase up to 581,199 additional shares, enhancing the flexibility of the financing and potential inflow of funds.
- Clinical Trial Progress: Ongoing Phase 3 trials, CHAPTER-3 and CREAATE, for the new drug deucrictibant are expected to provide critical data for market prospects, with topline results anticipated in Q3 2026, potentially boosting future market acceptance.
See More
Pharvaris to Present Research Findings at EAACI Congress
- Research Presentation: Pharvaris will showcase eight research findings at the 2026 EAACI Congress, including one oral presentation and seven poster presentations, highlighting advancements in treating hereditary angioedema, which is expected to enhance the company's visibility in the biopharmaceutical sector.
- Oral Presentation Highlights: The oral presentation will be led by Dr. Mauro Cancian, focusing on the immediate treatment effects of oral Deucrictibant capsules for hereditary angioedema attacks, providing crucial data support for clinical applications and potentially increasing market acceptance of the product.
- Poster Presentation Content: Several poster presentations will cover safety assessments of Deucrictibant and its applications in various treatment regimens, likely attracting the attention of clinicians and fostering future collaborations and research opportunities.
- Market Authorization Preparation: Pharvaris is preparing marketing authorization applications for the Deucrictibant immediate-release capsule and conducting a global pivotal Phase 3 study, with significant data expected in Q3 2026, which will lay the groundwork for the company's future growth.
See More
Pharvaris Reports Q1 2026 Financial Results
- Financial Performance: Pharvaris reported a GAAP EPS of -€0.59 for Q1 2026, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company's cash and cash equivalents stood at €247 million, down from €292 million on December 31, 2025, reflecting liquidity pressures that may affect future operations.
- Funding Activity: Pharvaris is planning a $115 million stock offering aimed at strengthening its capital base, although this may dilute existing shareholders and potentially exert downward pressure on the stock price in the short term.
- Conference Presentations: Pharvaris showcased its research at several key conferences, including the CIIC Spring Conference and the AAAAI Annual Meeting, aiming to enhance its visibility and influence in the industry while fostering potential collaboration opportunities.
See More
Analysis of Insider Stock Transaction at Pharvaris N.V.
- Insider Stock Sale: On May 1, 2026, Pharvaris N.V.'s Chief Medical Officer, Peng Lu, sold 14,166 common shares for approximately $427,000 through a scheduled option exercise and immediate sale, indicating routine portfolio management rather than opportunistic trading.
- Equity Exposure Analysis: Post-transaction, Lu retains 66,083 direct shares valued at about $1.95 million, reflecting a 17.65% reduction in direct holdings, yet maintains substantial equity exposure through 205,000 stock options, aligning with shareholder interests.
- Financial Overview: Pharvaris N.V. has a market capitalization of $1.97 billion, and despite a net loss of $175.7 million in 2025, the company invested €124 million in R&D, showcasing its long-term strategic focus in the rare disease treatment sector.
- Clinical Progress and Market Outlook: The company is advancing therapies like PHA121 and PHVS416 for hereditary angioedema, with plans to submit a new drug application in the first half of 2026, which could solidify its competitive position in the market.
See More
Pharvaris CMO Sells Shares, Reduces Holdings
- Insider Selling: On May 1, 2026, Pharvaris N.V.'s Chief Medical Officer Peng Lu sold 14,166 common shares for approximately $427,000, representing 17.65% of his direct holdings, reducing ownership to 66,083 shares, indicating a cautious outlook on the company's future.
- Transaction Context: The sale was executed as part of a scheduled option exercise and immediate sale, with all shares coming from direct holdings and no indirect entities involved, demonstrating adherence to a 10b5-1 trading plan to mitigate insider trading risks.
- Financial Condition: Pharvaris reported cash and cash equivalents of €292 million for Q4 2025, a slight increase from €281 million the previous year, but still faced a €176 million annual loss with €124 million in R&D expenses, highlighting the high cost pressures typical of clinical-stage biotechs.
- Market Outlook: Despite recent clinical successes in the HAE treatment space and plans to submit an approval application in the first half of 2026, the company remains unprofitable and faces intense competition, necessitating careful evaluation of its future growth potential by investors.
See More
Pharvaris Prices Underwritten Offering of 3.87 Million Shares
- Offering Size: Pharvaris has priced an underwritten offering of 3.87 million ordinary shares at $29.68 per share, with gross proceeds expected to be approximately $115 million, which will provide crucial funding for the company's research and operations.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 581,199 ordinary shares, which may further enhance the company's capital structure and market liquidity.
- Market Reaction: Following the announcement of the offering, Pharvaris's stock traded 1.5% higher during pre-market hours on Friday, indicating a positive market response to the company's financing activities and potentially boosting investor confidence.
- Future Outlook: The offering is expected to close on or about May 11, 2026, with the funds aimed at supporting the company's further development and innovation in the global angioedema space, thereby enhancing its competitive position in the market.
See More
Pharvaris Prices Underwritten Offering of 3,874,664 Shares
- Offering Size: Pharvaris announced the pricing of 3,874,664 ordinary shares at $29.68 each, expecting to raise approximately $115 million, reflecting the company's strong financing capability and market confidence in the biopharmaceutical sector.
- Underwriter Selection: Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the offering, indicating robust support and professional partnerships in the capital markets.
- Additional Share Option: Pharvaris granted underwriters a 30-day option to purchase up to 581,199 additional shares, enhancing the flexibility of the financing and potential inflow of funds.
- Clinical Trial Progress: Ongoing Phase 3 trials, CHAPTER-3 and CREAATE, for the new drug deucrictibant are expected to provide critical data for market prospects, with topline results anticipated in Q3 2026, potentially boosting future market acceptance.
See More
